title: Immunogenicity and protective efficacy of orally administered recombinant Lactococcus lactis expressing surface-bound HIV Env.
abstract: This study investigates whether genetically modified orally administered Lactococcus lactis (L lactis) could be used as an HIV vaccine. L lactis is immunogenic and extremely safe when delivered orally. We created a recombinant L lactis vector expressing the envelope protein of HIV on its cell surface. Oral immunization with this vector induced high levels of HIV-specific serum IgG and fecal IgA antibodies. Cell-mediated immune responses also were generated in both the regional lymph nodes and the spleen. Dendritic cells are readily infected by L lactis and appear to play a potential role in mediating the development of these immune responses. The protective efficacy of this vaccine strategy was demonstrated by challenging mice intraperitoneally with an HIV Env-expressing vaccinia virus. Their viral loads were 350-fold lower than those of control mice. These findings support the further development of L lactis-based HIV vaccines.
authors.affiliation: Department of Bacteriology, Yokohama City University School of Medicine, 3-9 Fukuura, Kanazawa-ku, Yokohama 236-0004, Japan.
authors.forename: Ke-Qin
authors.initials: KQ
authors.lastname: Xin
authors.forename: Yuka
authors.initials: Y
authors.lastname: Hoshino
authors.forename: Yoshihiko
authors.initials: Y
authors.lastname: Toda
authors.forename: Shizunobu
authors.initials: S
authors.lastname: Igimi
authors.forename: Yoshitsugu
authors.initials: Y
authors.lastname: Kojima
authors.forename: Nao
authors.initials: N
authors.lastname: Jounai
authors.forename: Kenji
authors.initials: K
authors.lastname: Ohba
authors.forename: Akira
authors.initials: A
authors.lastname: Kushiro
authors.forename: Mayumi
authors.initials: M
authors.lastname: Kiwaki
authors.forename: Kenji
authors.initials: K
authors.lastname: Hamajima
authors.forename: Dennis
authors.initials: D
authors.lastname: Klinman
authors.forename: Kenji
authors.initials: K
authors.lastname: Okuda
mesh_terms: D016915:AIDS Vaccines; D000284:Administration, Oral; D000818:Animals; D003713:Dendritic Cells / Q000276:immunology / Q000382:microbiology; D005260:Female; D005822:Genetic Vectors / Q000627:therapeutic use; D019302:HIV Envelope Protein gp160 / Q000008:administration & dosage* / Q000235:genetics / Q000276:immunology; D007111:Immunity, Cellular; D007074:Immunoglobulin G / Q000032:analysis; D007167:Immunotherapy / Q000379:methods*; D013294:Lactococcus lactis / Q000235:genetics; D051379:Mice; D008807:Mice, Inbred BALB C; D011994:Recombinant Proteins / Q000008:administration & dosage / Q000627:therapeutic use; D016896:Treatment Outcome; D014616:Vaccinia virus / Q000187:drug effects; D019562:Viral Load
chemical_list: D016915:AIDS Vaccines; D019302:HIV Envelope Protein gp160; D007074:Immunoglobulin G; D011994:Recombinant Proteins